Characterization of distinct immunophenotypes across pediatric brain tumor types.
Characterization of distinct immunophenotypes across pediatric brain tumor types.
复制标题
DOI:
10.4049/jimmunol.1301966
复制
发表时间:
2013-11-01
期刊:
影响因子:
--
通讯作者:
Foreman NK
中科院分区:
文献类型:
--
作者:
Griesinger AM;Birks DK;Donson AM;Amani V;Hoffman LM;Waziri A;Wang M;Handler MH;Foreman NK
Despite increasing evidence that anti-tumor immune control exists in the pediatric brain, these findings have yet to be exploited successfully in the clinic. A barrier to development of immunotherapeutic strategies in pediatric brain tumors is that the immunophenotype of these tumors’ microenvironment has not been defined. To address this the present study used multicolor FACS of disaggregated tumor to systematically characterize the frequency and phenotype of infiltrating immune cells in the most common pediatric brain tumor types. The initial study cohort consisted of 7 pilocytic astrocytoma (PA), 19 ependymoma (EPN), 5 glioblastoma (GBM), 6 medulloblastoma (MED) and 5 non-tumor brain (NT) control samples obtained from epilepsy surgery. Immune cell types analyzed included both myeloid and T-cell lineages and respective markers of activated or suppressed functional phenotypes. Immune parameters that distinguished each of the tumor types were identified. PA and EPN demonstrated significantly higher infiltrating myeloid and lymphoid cells compared to GBM, MED or NT. Additionally, PA and EPN conveyed a comparatively activated/M1-skewed myeloid functional phenotype denoted in particular by HLA-DR and CD64 expression. In contrast, GBM and MED contained progressively fewer infiltrating leukocytes and more muted functional phenotype similar to that of NT. These findings were recapitulated using whole tumor expression of corresponding immune marker genes in a large gene expression microarray cohort of pediatric brain tumors. The results of this cross-tumor comparative analysis demonstrate that different pediatric brain tumor types exhibit distinct immunophenotypes, implying that specific immunotherapeutic approaches may be most effective for each tumor type.
登录
查看更多内容
DOI:
10.1056/nejmoa1003466
发表时间:
2010-08-19
期刊:
The New England journal of medicine
影响因子:
--
作者:
Hodi FS;O'Day SJ;McDermott DF;Weber RW;Sosman JA;Haanen JB;Gonzalez R;Robert C;Schadendorf D;Hassel JC;Akerley W;van den Eertwegh AJ;Lutzky J;Lorigan P;Vaubel JM;Linette GP;Hogg D;Ottensmeier CH;Lebbé C;Peschel C;Quirt I;Clark JI;Wolchok JD;Weber JS;Tian J;Yellin MJ;Nichol GM;Hoos A;Urba WJ
通讯作者:
Urba WJ
DOI:
10.1097/01.jnen.0000183345.19447.8e
发表时间:
2005-10-01
影响因子:
3.2
作者:
Huang, H;Hara, A;Ohgaki, H
通讯作者:
Ohgaki, H
影响因子:
5.8
作者:
Diederichsen, ACP;Hjelmborg, JV;Fenger, C
通讯作者:
Fenger, C
影响因子:
15.9
作者:
Birks, Diane K.;Donson, Andrew M.;Foreman, Nicholas K.
通讯作者:
Foreman, Nicholas K.
影响因子:
158.5
作者:
Kantoff, Philip W.;Higano, Celestia S.;Young, J.
通讯作者:
Young, J.